US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
PR88826
SHANGHAI, Apr. 2, 2021 /Xinhua=KYODO JBN/--
On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2
neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai
Research Center, was approved by FDA for clinical trial in the United States.
Preclinical data showed that JMB2002 can precisely occupy the key epitope of
the receptor binding domain (RBD) on the S1 subunit of the SARS-CoV-2 with
human angiotensin-converting enzyme II (hACE2) binding interface, and has
strong binding and blocking activities to the spike glycoproteins of mutant
viruses including the South African mutant (B.1.351), the UK mutant (B.1.1.7)
and the Brazilian mutant (P.1) .
In February of this year, Jemincare researchers published on bioRxiv website a
paper entitled "A human antibody with blocking activity to RBD proteins of
multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and
therapeutic efficacy against SARS-CoV-2 in rhesus macaques". The preprint paper
reported that JMB2002 showed 6.8-fold and 1.9-fold higher binding affinity to
SARS-CoV-2 S1 mutant proteins of South African mutant and UK mutant
respectively in comparison to that of prototype S1, indicating that JMB2002
would likely keep the neutralize potency against the South Africa and UK
mutants. In the latest lab study, JMB2002 also showed 7-fold higher affinity to
S1 RBD of Brazilian variant compared to prototype S1 RBD, suggesting that
JMB2002 would also likely retain the neutralize potency against the Brazilian
variant.
In the middle of January, 2021, Jemincare has initiated the phase I clinical
trial of Chinese healthy subjects. Dosing of all cohorts is completed in the
phase I clinical trial in China. Now, JMB2002 was approved by FDA for clinical
trial in US, that would add an option for prophylactic and therapeutic
intervention of SARS-CoV-2 utilizing JMB2002 to slow down the transmission of
currently emerged SARS-CoV-2 variants and that would likely result in more
efficient control of the COVID-19 pandemic.
As one of the top pharmaceutical groups in China, Jemincare Group, has focused
on the R&D of new drugs with pipeline for treating diseases in cancer, central
nervous system, respiratory system, cardiovascular and cerebrovascular systems.
Jemincare has established its Research Center in Shanghai Zhangjiang Science
City and has recruited over 400 R&D scientists for development of innovative
drugs including biologics, novel small molecules, novel drug delivery system,
generic drugs and traditional Chinese medicines.
For more information, please visit: http://www.jemincare.com/, or contact:
PR@jemincare.com
Source: Jemincare
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。